

CITATION REPORT

List of articles citing

The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28

DOI: 10.1001/archopht.124.12.1684
JAMA Ophthalmology, 2006, 124, 1684-93.

Source: <https://exaly.com/paper-pdf/41119815/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
517	Comparison of survival among eligible patients not enrolled versus enrolled in the Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. 2007 , 14, 251-7		6
516	Legacy of the collaborative ocular melanoma study. <i>JAMA Ophthalmology</i> , 2007 , 125, 966-8		32
515	The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma: V. Twelve-Year Mortality Rates and Prognostic Factors: COMS Report No. 28. 2007 , 2007, 241-242		1
514	The investigators' perspective on the collaborative ocular melanoma study. <i>JAMA Ophthalmology</i> , 2007 , 125, 968-71		5
513	(106)Ruthenium brachytherapy for retinoblastoma. 2008 , 71, 821-8		39
512	Two differing presentations, treatments, and outcomes of malignant choroidal melanoma. 2008 , 79, 365-70		4
511	Artificial neural networks estimating survival probability after treatment of choroidal melanoma. 2008 , 115, 1598-607		59
510	The future promise and the current reality of genetic prognostication in patients with uveal melanoma. <i>JAMA Ophthalmology</i> , 2008 , 126, 413-5		4
509	Choroidal melanoma endoresection, dandelions and allegory-based medicine. 2008 , 92, 1013-4		24
508	Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy. 2008 , 35, 5530-43		65
507	Endoresection in high posterior choroidal melanomas: long-term outcome. 2008 , 92, 1040-5		26
506	Histopathologic characteristics of choroidal melanoma in eyes enucleated after iodine 125 brachytherapy in the collaborative ocular melanoma study. <i>JAMA Ophthalmology</i> , 2008 , 126, 207-12		45
505	Survival in patients with uveal melanoma in Europe. <i>JAMA Ophthalmology</i> , 2008 , 126, 1413-8		78
504	Assessment of central vision and macular structure in patients undergoing iodine-125 brachytherapy for ciliochoroidal melanoma. 2008 , 31, 488-92		2
503	Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis. 2008 , 18, 191-200		99
502	Regression of uveal melanoma after plaque radiotherapy and thermotherapy based on chromosome 3 status. 2008 , 28, 1289-95		28
501	Stereotactic radiotherapy for treatment of juxtapapillary choroidal melanoma: 3-year follow-up. 2009 , 93, 1172-6		52

500	Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. <i>JAMA Ophthalmology</i> , 2009 , 127, 989-98	336
499	A first report of radioembolization for hepatic metastases from ocular melanoma. 2009 , 27, 682-90	65
498	(125)I episcleral plaque brachytherapy in the treatment of choroidal melanoma: a single-institution experience in Spain. 2009 , 8, 290-6	19
497	A reappraisal of the significance of largest basal diameter of posterior uveal melanoma. 2009 , 23, 2152-60; quiz 2161-2	58
496	Ocular complications following I-125 brachytherapy for choroidal melanoma. 2009 , 23, 1254-68	56
495	Long-term survival of uveal melanoma patients after surgery for liver metastases. 2009 , 93, 1042-6	68
494	I-125 brachytherapy for choroidal melanoma photographic and angiographic abnormalities: the Collaborative Ocular Melanoma Study: COMS Report No. 30. 2009 , 116, 106-115.e1	46
493	Palladium-103 ophthalmic plaque radiation therapy for choroidal melanoma: 400 treated patients. 2009 , 116, 790-6, 796.e1	89
492	Uveal melanoma in the Saudi Arabian population: Two decades of management at the King Khaled Eye Specialist Hospital. 2009 , 23, 157-63	5
491	Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy with various seed models. 2010 , 37, 368-76	32
490	Stereotactic radiotherapy in the treatment of juxtapapillary choroidal melanoma: 2-year follow-up. 2009 , 44, 61-5	12
489	Management of ciliary body melanoma with iodine-125 plaque brachytherapy. 2009 , 44, 395-400	12
488	Update on posterior uveal melanoma: treatment of the eye and emerging strategies in the prognosis and treatment of metastatic disease. 2009 , 20, 504-10	15
487	Attenuation of iodine 125 radiation with vitreous substitutes in the treatment of uveal melanoma. <i>JAMA Ophthalmology</i> , 2010 , 128, 888-93	36
486	Comparison of dose calculation methods for brachytherapy of intraocular tumors. 2011 , 38, 306-16	51
485	A comprehensive dosimetric comparison between (131)Cs and (125)I brachytherapy sources for COMS eye plaque implant. 2010 , 9, 362-72	27
484	Protonenstrahlentherapie bei Aderhautmelanomen des hinteren Augenpols. 2010 , 24, 11-16	2
483	Does ocular treatment of uveal melanoma influence survival?. 2010 , 103, 285-90	78

482	Surgery of primary melanomas. 2010 , 2, 824-41	10
481	Ten-year results of transscleral resection of large uveal melanomas: local tumour control and metastatic rate. 2010 , 94, 460-6	31
480	Modified enucleation for choroidal melanoma with large extrascleral extension. 2010 , 29, 70-5	5
479	Melanome uvéal postérieur (choroïde et/ou corps ciliaire). 2010 , 127-132	
478	Curcumin induces cell death in human uveal melanoma cells through mitochondrial pathway. 2010 , 35, 352-60	22
477	Ocular neoplastic disease. 2011 , 32, 28-37	24
476	Preoperative evaluation for patients with choroidal/ciliary body melanomas: what is necessary?. 2011 , 151, 921-4	6
475	Ruthenium-106 brachytherapy. 2012 , 49, 27-40	19
474	Plaque radiotherapy for juxtapapillary choroidal melanoma: tumor control in 650 consecutive cases. 2011 , 118, 402-7	45
473	Ocular response of choroidal melanoma with monosomy 3 versus disomy 3 after iodine-125 brachytherapy. 2011 , 81, 1046-8	17
472	Intraocular pressure elevation during radioactive plaque brachytherapy for uveal melanoma. <i>JAMA Ophthalmology</i> , 2011 , 129, 668-9	2
471	Uveal metastatic disease: current and new treatment options (review). 2012 , 27, 603-7	13
470	Local control and visual acuity following treatment of medium-sized ocular melanoma using a contact eye plaque: a single surgeon experience. 2011 , 10, 228-31	8
469	A 17-year retrospective study of institutional results for eye plaque brachytherapy of uveal melanoma using (125)I, (103)Pd, and (131)Cs and historical perspective. 2011 , 10, 331-9	35
468	VEGF as a biomarker for metastatic uveal melanoma in humans. 2011 , 36, 386-90	37
467	Collaborative ocular melanoma study randomized trial of I-125 brachytherapy. 2011 , 8, 661-73	35
466	A Rare Case of Congenital Ocular Melanoma in a 3-Year-Old Child. 2011 , 2, 166-168	1
465	Juxtapapillary uveal melanomas: patient outcomes after treatment with proton irradiation for peripapillary and parapapillary melanomas. <i>JAMA Ophthalmology</i> , 2011 , 129, 1218-20	4

464	Microarray gene-expression analysis in ocular oncology: uveal melanoma and retinoblastoma. 2011 , 6, 477-485	1
463	Current treatment of choroidal melanoma. 2012 , 7, 189-195	1
462	Relative survival of patients with uveal melanoma managed in a single center. 2012 , 22, 271-7	15
461	Comparison of clinical outcomes for patients with large choroidal melanoma after primary treatment with enucleation or proton beam radiotherapy. 2012 , 227, 190-6	19
460	Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS. 2012 , 39, 6161-84	125
459	Choroidal melanoma. 2012 , 5, 3-9	47
458	Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. 2012 , 32, 1363-72	182
457	Outcomes of proton radiation therapy for peripapillary choroidal melanoma at the BC Cancer Agency. 2012 , 83, 1425-31	25
456	Fractionated stereotactic radiotherapy for uveal melanoma, late clinical results. 2012 , 102, 219-24	25
455	Practical steps for establishing ocular plaque therapy in developing countries. 2012 , 11, 230-6	5
454	Uveal melanoma prognostication: from lesion size and cell type to molecular class. 2012 , 47, 246-53	43
453	Intraoperative ultrasonography-guided positioning of iodine 125 plaque brachytherapy in the treatment of choroidal melanoma. 2012 , 119, 1073-7	65
452	Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture. 2012 , 26, 1157-72	96
451	Epidemiology and management of uveal melanoma. 2012 , 26, 1169-84	46
450	Evaluation of material heterogeneity dosimetric effects using radiochromic film for COMS eye plaques loaded with (125)I seeds (model I25.S16). 2013 , 40, 011708	4
449	Serum DJ-1/PARK 7 is a potential biomarker of choroidal nevi transformation. 2012 , 53, 62-7	22
448	Expression of 12 cytokines in aqueous humour of uveal melanoma before and after combined Ruthenium-106 brachytherapy and transpupillary thermotherapy. 2012 , 90, e314-20	14
447	The effects of variations in the density and composition of eye materials on ophthalmic brachytherapy dosimetry. 2012 , 37, 1-4	5

446	Proton Therapy for Conditions of the Eye. 2013 , 97-104	
445	Novel 3D conformal technique for treatment of choroidal melanoma with external beam photon radiotherapy. 2013 , 57, 230-6	3
444	Long-term results of carbon ion radiation therapy for locally advanced or unfavorably located choroidal melanoma: usefulness of CT-based 2-port orthogonal therapy for reducing the incidence of neovascular glaucoma. 2013 , 86, 270-6	29
443	[Uveal melanoma: clinical characteristics, treatment and survival in a series of 500 patients]. 2013 , 88, 433-8	5
442	Proton Beam Therapy. 2013 ,	2
441	Brachytherapy for Choroidal Melanoma. 2013 , 2275-2289	
440	Overview of Management of Posterior Uveal Melanoma. 2013 , 2267-2270	1
439	Nonrhegmatogenous Retinal Detachment. 2013 , 1622-1639	1
438	Pathology of Choroidal Melanoma. 2013 , 2254-2266.e2	
437	Collaborative Ocular Melanoma Study. 2013 , 2316-2323	
436	Gamma-knife-based stereotactic radiosurgery for medium- and large-sized posterior uveal melanoma. 2013 , 251, 285-94	23
435	Uveal melanoma: Clinical characteristics, treatment and survival in a series of 500 patients. 2013 , 88, 433-438	
434	Metastasis from uveal melanoma associated with congenital ocular melanocytosis: a matched study. 2013 , 120, 1465-8	9
433	Quantifying the dosimetric influences of radiation coverage and brachytherapy implant placement uncertainty on eye plaque size selection. 2013 , 12, 508-20	24
432	American Joint Committee on Cancer classification of posterior uveal melanoma (tumor size category) predicts prognosis in 7731 patients. 2013 , 120, 2066-71	92
431	Scleral necrosis after plaque radiotherapy of uveal melanoma: a case-control study. 2013 , 120, 1004-11	35
430	Palladium-103 radiation therapy for small choroidal melanoma. 2013 , 120, 2353-7	26
429	Charged particle radiation therapy for uveal melanoma: a systematic review and meta-analysis. 2013 , 86, 18-26	69

428	Radiation therapy: uveal tumors. 2013 , 52, 36-57	10
427	Local treatment failure after globe-conserving therapy for choroidal melanoma. 2013 , 97, 804-11	57
426	Rapidly enlarging choroidal melanoma: perioperative treatment implications. 2013 , 7, 75-7	
425	Diffuse versus nondiffuse small (13 MM thickness) choroidal melanoma: comparative analysis in 1,751 cases. The 2012 F. Phinizy Calhoun lecture. 2013 , 33, 1763-76	24
424	Role of vitreoretinal surgery in maximizing treatment outcome following complications after proton therapy for uveal melanoma. 2013 , 33, 1777-83	8
423	Delayed systemic recurrence of uveal melanoma. 2013 , 36, 443-9	20
422	Imaging errors in localization of COMS-type plaques in choroidal melanoma brachytherapy. 2013 , 54, 6852-60	7
421	Quality of life in the follow-up of uveal melanoma patients after CyberKnife treatment. 2013 , 23, 481-8	16
420	Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. 2013 , 24, 2911-5	102
419	Indigenous (125)I brachytherapy source for the management of intraocular melanomas in India. 2013 , 28, 21-8	6
418	Gender differences in clinical presentation and prognosis of uveal melanoma. 2013 , 54, 652-6	46
417	Microincisional vitrectomy for retinal detachment in I-125 brachytherapy-treated patients with posterior uveal malignant melanoma. 2013 , 7, 427-35	8
416	Intravitreal bevacizumab combined with plaque brachytherapy reduces melanoma tumor volume and enhances resolution of exudative detachment. 2013 , 7, 193-8	16
415	Influence of age on prognosis of young patients with uveal melanoma: a matched retrospective cohort study. 2013 , 23, 208-16	30
414	Current and emerging treatment options for uveal melanoma. 2013 , 7, 1669-82	56
413	Ocular Tumors. 2014 , 2179-2200	1
412	Squamous Cell Carcinoma Metastatic to the Choroid. 2014 , 05,	0
411	Outcomes and control rates for I-125 plaque brachytherapy for uveal melanoma: a community-based institutional experience. 2014 , 2014, 950975	16

410	Carbon-Ion Radiotherapy. 2014,	43
409	Evidence-based integration of selective internal radiation therapy into the management of ocular melanoma liver metastases. 2014, 10, 97-100	
408	Model-based dose calculations for COMS eye plaque brachytherapy using an anatomically realistic eye phantom. 2014, 41, 021717	24
407	Implication of ultraviolet light in the etiology of uveal melanoma: A review. 2014, 90, 15-21	24
406	Re-emphasizing Thygeson® warning: conjunctival phlyctenulosis as presenting sign of impending clinical tuberculosis. 2014, 49, e135-7	3
405	Orbital extension of anterior uveal melanoma after Baerveldt tube shunt implantation. 2014, 49, e133-5	4
404	Detecting ultrasonographic hollowness in small choroidal melanocytic tumors using 10 MHz and 20 MHz ultrasonography: a comparative study. 2014, 252, 2005-11	3
403	Uveal melanoma: A pathologist® perspective and review of translational developments. 2014, 21, 138-43	22
402	Clinical Ophthalmic Oncology. 2014,	2
401	Age, survival predictors, and metastatic death in patients with choroidal melanoma: tentative evidence of a therapeutic effect on survival. 2014, 132, 605-13	61
400	Abstracts of the European Vitreoretinal update 14th Euretina Congress, 2014, London, England. 2014, 232 Suppl 1, 1-36	12
399	Choroidal melanoma: clinical features, classification, and top 10 pseudomelanomas. 2014, 25, 177-85	70
398	The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. 2014, 13, 1-14	208
397	Monte Carlo dosimetry for 103Pd, 125I, and 131Cs ocular brachytherapy with various plaque models using an eye phantom. 2014, 41, 031706	14
396	Brachytherapy Physics. 2014, 315-381	0
395	Monte Carlo dosimetry of the eye plaque design used at the St. Erik Eye Hospital for (125)I brachytherapy. 2014, 13, 651-6	6
394	Dosimetry for 131Cs and 125I seeds in solid water phantom using radiochromic EBT film. 2014, 92, 102-14	14
393	Brachytherapy and endoresection for choroidal melanoma: a cohort study. 2014, 98, 86-91	11

392	Bimodal mortality dynamics for uveal melanoma: a cue for metastasis development traits?. 2014 , 14, 392	11
391	Assessment of the effect of iris colour and having children on 5-year risk of death after diagnosis of uveal melanoma: a follow-up study. 2014 , 14, 42	11
390	Disease control and toxicity outcomes using ruthenium eye plaque brachytherapy in the treatment of uveal melanoma. 2014 , 4, e189-94	17
389	Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. 2014 , 88, 986-97	112
388	Uveal melanoma treated with iodine-125 episcleral plaque: an analysis of dose on disease control and visual outcomes. 2014 , 89, 127-36	42
387	Reirradiation of the eye with plaque brachytherapy: a single institution experience report of eight consecutive patients submitted to retreatment after local relapse of malignant disease of the eye. 2014 , 13, 281-4	8
386	Treatments for noncutaneous melanoma. 2014 , 28, 507-21	11
385	Iodine 125 brachytherapy with vitrectomy and silicone oil in the treatment of uveal melanoma: 1-to-1 matched case-control series. 2014 , 89, 347-52	27
384	(106)Ru plaque brachytherapy for uveal melanoma: factors associated with local tumor recurrence. 2014 , 13, 584-90	24
383	Regression of uveal melanoma after ru-106 brachytherapy and thermotherapy based on metabolic activity measured by positron emission tomography/computed tomography. 2014 , 34, 182-7	5
382	Proton beam radiotherapy for uveal melanoma. 2015 , 10, 577-585	3
381	Detection of circulating melanoma cells in choroidal melanocytic lesions. 2015 , 8, 452	15
380	Preliminary results of contrast-enhanced sonography in the evaluation of the response of uveal melanoma to gamma-knife radiosurgery. 2015 , 43, 421-30	5
379	Cost-effectiveness of proton beam therapy for intraocular melanoma. 2015 , 10, e0127814	16
378	iTRAQ Quantitative Proteomic Comparison of Metastatic and Non-Metastatic Uveal Melanoma Tumors. 2015 , 10, e0135543	18
377	Clinical Characteristics of 582 Patients with Uveal Melanoma in China. 2015 , 10, e0144562	14
376	ME20-S as a Potential Biomarker for the Evaluation of Uveal Melanoma. 2015 , 56, 7007-11	8
375	Endoresection technique with/without brachytherapy for management of high posterior choroidal melanoma: extended follow-up results. 2015 , 35, 628-37	24

- 374 Uveal melanoma: evidence for efficacy of therapy. **2015**, 55, 23-43 10
- 373 Melanoma. **2015**, 88-99
- 372 Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling. **2015**, 14, 718-25 13
- 371 A biological tissue adhesive and dissolvent system for intraocular tumor plaque radiotherapy: an in vivo animal model experiment. **2015**, 253, 1923-31 2
- 370 The potential complementary role of targeted alpha therapy in the management of metastatic melanoma. **2015**, 2, 353-366 1
- 369 Long-term Risk of Melanoma-Related Mortality for Patients With Uveal Melanoma Treated With Proton Beam Therapy. **2015**, 133, 792-6 38
- 368 Management of posterior uveal melanoma: past, present, and future: the 2014 Charles L. Schepens lecture. **2015**, 122, 414-28 76
- 367 Heterogeneous dose calculations for Collaborative Ocular Melanoma Study eye plaques using actual seed configurations and Task Group Report 43 formalism. **2015**, 14, 209-30 7
- 366 Melanoma of the eye: revealing hidden secrets, one at a time. **2015**, 33, 183-96 42
- 365 Noninvasive diagnostics supporting system for choroidal melanoma: a pilot study. **2015**, 59, 48-54 2
- 364 Incidence and indications for pars plana vitrectomy following the treatment of posterior uveal melanomas in Scotland. **2015**, 29, 748-56 4
- 363 Uveal melanoma: estimating prognosis. **2015**, 63, 93-102 125
- 362 [Late marginal recurrence of a choroidal melanoma after initially effective brachytherapy]. **2015**, 38, e15-8
- 361 Long-term Results of the UCSF-LBNL Randomized Trial: Charged Particle With Helium Ion Versus Iodine-125 Plaque Therapy for Choroidal and Ciliary Body Melanoma. **2015**, 92, 376-83 48
- 360 A choice of radionuclide: Comparative outcomes and toxicity of ruthenium-106 and iodine-125 in the definitive treatment of uveal melanoma. **2015**, 5, e169-e176 29
- 359 International Validation of the American Joint Committee on Cancer® 7th Edition Classification of Uveal Melanoma. **2015**, 133, 376-83 94
- 358 [Malignant tumours of the eye: Epidemiology, diagnostic methods and radiotherapy]. **2015**, 19, 762-74 5
- 357 Radiation as a foundation for glioblastoma therapy in elderly patients. In Regard to Arvold et al. **2015**, 93, 217-8

356	Rare tumors: an eye on the future. 2015 , 11, 2641-2644	3
355	Secondary Eucleations for Uveal Melanoma: A 7-Year Retrospective Analysis. 2015 , 160, 1104-1110.e1	12
354	In Reply to Kamrava and McCannel. 2015 , 93, 216-7	1
353	Progressive Scleral Necrosis following I-125 Plaque Radiotherapy for Ciliochoroidal Melanoma with Protruding Extraocular Mass. 2016 , 2, 136-9	2
352	Management of uveal melanoma: a consensus-based provincial clinical practice guideline. 2016 , 23, e57-64	43
351	Management and Outcome of Uveal Melanoma in a Single Tertiary Cancer Center in Jordan. 2016 , 32, 186-92	2
350	Clinical Performance and Management Outcomes with the DecisionDx-UM Gene Expression Profile Test in a Prospective Multicenter Study. 2016 , 2016, 5325762	29
349	Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate. 2016 , 8, 66-73	28
348	Overexpression of Annexin II Receptor-Induced Autophagy Protects Against Apoptosis in Uveal Melanoma Cells. 2016 , 31, 145-51	10
347	Point/Counterpoint. Particle therapy is ideal for the treatment of ocular melanomas. 2016 , 43, 631-4	6
346	Delivered dose uncertainty analysis at the tumor apex for ocular brachytherapy. 2016 , 43, 4891	7
345	Antiangiogenic or Corticosteroid Treatment in Patients With Radiation Maculopathy After Proton Beam Therapy for Uveal Melanoma. 2016 , 168, 31-39	23
344	Uveal Melanocytic Tumors. 5-19	1
343	Tumor Characteristics, Genetics, Management, and the Risk of Metastasis in Uveal Melanoma. 2016 , 31, 304-9	31
342	The Alberta Ocular Brachytherapy Program: Utilization of Patient Feedback to Guide Improvements. 2016 , 47, 349-355	
341	Investigating the dosimetric impact of seed location uncertainties in Collaborative Ocular Melanoma Study-based eye plaques. 2016 , 15, 661-8	3
340	23-mm iodine-125 plaque for uveal melanoma: benefit of vitrectomy and silicone oil on visual acuity. 2016 , 254, 2461-2467	9
339	[Indications and results for protontherapy in cancer treatments]. 2016 , 20, 513-8	3

338	Dosimetric quality of partially loaded I-125 COMS eye plaques for practical placement on posterior tumors. 2016 ,	
337	Tumor-height regression rate after brachytherapy between choroidal melanoma gene expression profile classes: effect of controlling for tumor height. 2016 , 254, 1371-8	12
336	Low-dose brachytherapy strategies to treat uveal melanoma: is less more?. 2016 , 3, 13-22	0
335	Clinical Outcomes of Proton Radiotherapy for Uveal Melanoma. 2016 , 28, e17-27	46
334	Role of radiation therapy in melanomas: Systematic review and best practice in 2016. 2016 , 99, 362-75	11
333	Quality of life in the follow-up of uveal melanoma patients after enucleation in comparison to CyberKnife treatment. 2016 , 254, 1005-12	10
332	Outcomes After Proton Beam Therapy for Large Choroidal Melanomas in 492 Patients. 2016 , 165, 78-87	28
331	Brachytherapy vs. external beam radiotherapy for choroidal melanoma: Survival and patterns-of-care analyses. 2016 , 15, 216-23	16
330	Treatment of Uveal Melanoma. 2016 , 167, 281-93	14
329	Long-term visual acuity outcomes in patients with uveal melanoma treated with 125I episcleral OSU-Nag plaque brachytherapy. 2016 , 15, 12-22	20
328	Brachytherapy. 2016 , 276-293.e5	1
327	The role of chemical elements in melanoma. 2017 , 2, 73	
326	Stereotactic Radiosurgery and Fractionated Stereotactic Radiation Therapy for the Treatment of Uveal Melanoma. 2017 , 98, 152-158	13
325	Metastatic disease from uveal melanoma: treatment options and future prospects. 2017 , 101, 38-44	178
324	Dosimetric and radiobiologic comparison of Pd COMS plaque brachytherapy and Gamma Knife radiosurgery for choroidal melanoma. 2017 , 16, 433-443	6
323	Efficacy of curcumin in inducing apoptosis and inhibiting the expression of VEGF in human pterygium fibroblasts. 2017 , 39, 1149-1154	8
322	Use of Protons for Radiation Therapy. 2017 , 115-140	1
321	Uveal melanoma: relatively rare but deadly cancer. 2017 , 31, 241-257	228

320	Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies. 2017 , 19, 45	58
319	Pattern of Local Recurrence After I-125 Episcleral Brachytherapy for Uveal Melanoma in a Spanish Referral Ocular Oncology Unit. 2017 , 180, 39-45	10
318	Visual acuity, oncologic, and toxicity outcomes with Pd vs. I plaque treatment for choroidal melanoma. 2017 , 16, 646-653	9
317	Early outcomes of uveal melanoma treated with intraoperative ultrasound guided brachytherapy using custom built plaques. 2017 , 7, e275-e282	15
316	Clinical and Imaging Features of Noncutaneous Melanoma. 2017 , 208, 942-959	23
315	Clinicopathological Characteristics and Prognosis for Survival after Enucleation of Uveal Melanoma in Chinese Patients: Long-term Follow-up. 2017 , 42, 759-765	11
314	Iodine-125 Brachytherapy for Uveal Melanoma: A Systematic Review of Radiation Dose. 2017 , 3, 193-198	27
313	Patterns of care and outcomes of proton and eye plaque brachytherapy for uveal melanoma: Review of the National Cancer Database. 2017 , 16, 1225-1231	12
312	Comparison of primary and secondary enucleation for uveal melanoma. 2017 , 36, 422-427	4
311	Surgery vs. radiotherapy in patients with uveal melanoma : Analysis of the SEER database using propensity score matching and weighting. 2017 , 193, 931-942	10
310	Growth of Uveal Melanoma following Intravitreal Bevacizumab. 2017 , 3, 117-121	12
309	Evaluating Retinal Sequelae of Radioactive Episcleral Plaque Brachytherapy for Medium-Sized Choroidal Melanomas Using Optical Coherence Tomography Angiography. 2017 , 2, 119-133	1
308	Modern and Novel Radiotherapy Approaches for the Treatment of Uveal Melanoma. 2017 , 57, 11-27	7
307	14 Radiotherapy of Orbital Diseases. 2017 ,	
306	Uveal Melanoma Treatment and Prognostication. 2017 , 6, 186-196	43
305	Patterns of care and survival outcomes after treatment for uveal melanoma in the post-coms era (2004-2013): a surveillance, epidemiology, and end results analysis. 2017 , 9, 453-465	22
304	INTERACTS (INTERventional Radiotherapy ACTIVE Teaching School) guidelines for quality assurance in choroidal melanoma interventional radiotherapy (brachytherapy) procedures. 2017 , 9, 287-295	25
303	Uveal melanoma: epidemiology, etiology, and treatment of primary disease. 2017 , 11, 279-289	147

302	Gene expression profiling in uveal melanoma: technical reliability and correlation of molecular class with pathologic characteristics. 2017 , 12, 59	17
301	Sex Disparity in Survival of Patients With Uveal Melanoma: Better Survival Rates in Women Than in Men in South Korea. 2017 , 58, 1909-1915	5
300	Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers. 2017 , 37, 641-650	6
299	Initial evaluation of Advanced Collapsed cone Engine dose calculations in water medium for I-125 seeds and COMS eye plaques. 2018 , 45, 1276-1286	3
298	Treatment of uveal melanoma: where are we now?. 2018 , 10, 1758834018757175	136
297	Clinical Predictors of Regression of Choroidal Melanomas after Brachytherapy: A Growth Curve Model. 2018 , 125, 747-754	6
296	Antitumor efficacy of VP22-CD/5-FC suicide gene system mediated by lentivirus in a murine uveal melanoma model. 2018 , 172, 144-151	7
295	Radiologic and Histopathologic Correlation of Different Growth Patterns of Metastatic Uveal Melanoma to the Liver. 2018 , 125, 597-605	12
294	Characteristics, management, and outcome of patients with uveal melanoma treated by Iodine-125 radioactive plaque therapy in a single tertiary cancer center in Jordan. 2018 , 32, 130-133	2
293	An Infrared Dye-Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma. 2018 , 17, 565-574	29
292	Comparative outcomes and toxicities for ruthenium-106 versus palladium-103 in the treatment of choroidal melanoma. 2018 , 28, 120-125	4
291	Programmed cell death ligand-1 expression in tumor and immune cells is associated with better patient outcome and decreased tumor-infiltrating lymphocytes in uveal melanoma. 2018 , 31, 1201-1210	16
290	Patient-reported Outcomes and Quality of Life After Treatment of Choroidal Melanoma: A Comparison of Enucleation Versus Radiotherapy in 1596 Patients. 2018 , 193, 230-251	22
289	[CyberKnife® : new treatment option for uveal melanoma]. 2018 , 115, 302-308	2
288	MRI-based treatment planning and dose delivery verification for intraocular melanoma brachytherapy. 2018 , 17, 31-39	15
287	Proton Beam Therapy for Iris Melanomas in 107 Patients. 2018 , 125, 606-614	13
286	Windowless extrapolation chamber measurement of surface dose rate from a 90Sr/90Y ophthalmic applicator. 2018 , 108, 34-40	6
285	Fine-Needle Aspiration Biopsy for Molecular Genomic Classification: Evaluation of Transscleral vs Transvitreal Biopsy. 2018 , 2, 208-212	1

284	99mTc-3PRGD2 single-photon emission computed tomography/computed tomography for the diagnosis of choroidal melanoma: A preliminary STROBE-compliant observational study. 2018 , 97, e12441	2
283	Outcomes of I-125 brachytherapy for uveal melanomas depending on irradiation dose applied to the tumor apex - a single institution study. 2018 , 10, 532-541	8
282	A national survey of AIRO (Italian Association of Radiation Oncology) brachytherapy (Interventional Radiotherapy) study group. 2018 , 10, 254-259	23
281	Scleral Thinning after Transscleral Biopsy for Uveal Melanoma Using Lamellar Scleral Flap. 2018 , 4, 381-387	2
280	RETINA. 2018 , 38, S1-S61	
279	Prognostic Factors and Decision Tree for Long-Term Survival in Metastatic Uveal Melanoma. 2018 , 50, 1130-1139	11
278	Visual Outcome and Millimeter Incremental Risk of Metastasis in 1780 Patients With Small Choroidal Melanoma Managed by Plaque Radiotherapy. 2018 , 136, 1325-1333	19
277	Quality of life: fractionated stereotactic radiotherapy versus enucleation treatment in uveal melanoma patients. 2018 , 96, 841-848	10
276	Uveal melanoma survival rates after single dose stereotactic radiosurgery. 2018 , 65, 965-971	7
275	Recent advancements in the management of retinoblastoma and uveal melanoma. 2018 , 7,	19
274	New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma. 2018 , 16, 646-650	25
273	Neoadjuvant proton beam irradiation vs. adjuvant ruthenium brachytherapy in transscleral resection of uveal melanoma. 2018 , 256, 1767-1775	6
272	Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152). 2018 , 123, 371-376	3
271	Gamma Knife radiosurgery for locally recurrent choroidal melanoma following plaque radiotherapy. 2018 , 4, 23	6
270	Evidence for Dose De-escalation in Brachytherapy for Choroidal Melanoma. 2018 , 3, 139-153	3
269	Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone. 2018 , 6, 13	17
268	Dose-response in choroidal melanoma. 2018 , 127, 374-378	2
267	Malignant and Benign Diseases of the Eye and Orbit. 2018 , 109-135	

266	Stereotactic radiotherapy for choroidal melanomas by means of HybridArc Physics and technique of linac-based photon beam therapy. 2018 , 194, 929-943	4
265	ICG-001 Exerts Potent Anticancer Activity Against Uveal Melanoma Cells. 2018 , 59, 132-143	13
264	Monte Carlo dosimetry modeling of focused kV x-ray radiotherapy of eye diseases with potential nanoparticle dose enhancement. 2018 , 45, 4720-4733	3
263	Outcomes of cataract surgery in eyes with ocular melanoma treated with iodine-125 brachytherapy. 2018 , 44, 287-294	0
262	Uveal Melanoma. 2018 , 273-312	2
261	Does NEMO/IKK β protein have a role in determining prognostic significance in uveal melanoma?. 2018 , 20, 1592-1603	2
260	Advanced Collapsed cone Engine dose calculations in tissue media for COMS eye plaques loaded with I-125 seeds. 2018 , 45, 3349-3360	6
259	Outcomes of Glaucoma Drainage Device Surgery in Eyes with Treated Uveal Melanoma. 2019 , 5, 20-27	1
258	Ocular Melanoma. 2019 , 453-468	
257	Uveal Melanoma Biopsy: A Review. 2019 , 11,	14
256	Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma. 2019 , 11,	50
255	Breakdown of the blood-eye barrier in choroidal melanoma after proton beam radiotherapy. 2019 , 257, 2323-2328	4
254	Ocular Oncology. 2019 ,	
253	Management of Patients with Posterior Uveal Melanoma. 2019 , 185-199	1
252	Uveal Melanoma: The Collaborative Ocular Melanoma Study. 2019 , 261-272	
251	Uveal Melanoma: Brachytherapy. 2019 , 201-217	1
250	Uveal melanoma: an overview of management and prognosis. 2019 , 46, 95-104	1
249	Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry. 2019 , 11,	16

248	Immunotherapies for the Treatment of Uveal Melanoma-History and Future. 2019 , 11,	34
247	Ultrasonography and transillumination for uveal melanoma localisation in proton beam treatment planning. 2019 , 33, 1904-1910	4
246	Molecular Characteristics of Uveal Melanoma: Insights from the Cancer Genome Atlas (TCGA) Project. 2019 , 11,	30
245	Brachytherapy: An overview for clinicians. 2019 , 69, 386-401	85
244	Preliminary results of a semi-automated platform for pixel-based quantification of choroidal naevus progression. 2019 , 54, 601-605	
243	Experimental validation of a new COMS-like 24´mm eye plaque for the treatment of large ocular melanoma tumors. 2019 , 18, 890-897	4
242	Fundus Autofluorescence Change as an Early Indicator of Treatment Effect of Brachytherapy for Choroidal Melanomas. 2019 , 5, 445-453	1
241	Delivered dose changes in COMS plaque-based ocular brachytherapy arising from vitrectomy with silicone oil replacement. 2019 , 18, 668-674	2
240	Complications and adverse events of plaque brachytherapy for ocular melanoma. 2019 , 11, 392-397	7
239	Head and Neck Cancers. 2019 , 133-196	
238	Computing uveal melanoma basal diameters: a comparative analysis of several novel techniques with improved accuracy. 2019 , 5, 2	2
237	Absolute Clinical Radiation Oncology Review. 2019 ,	2
236	Risk factors, clinical outcomes, and natural history of uveal melanoma: a single-institution analysis. 2019 , 36, 17	4
235	Variability of Bad Prognosis in Uveal Melanoma. 2019 , 3, 186-193	6
234	[New treatment options for iridociliary tumors]. 2019 , 116, 332-339	2
233	Choroidal Melanoma. 2019 , 13-26	1
232	New Insights into Molecular Oncogenesis and Therapy of Uveal Melanoma. 2019 , 11,	17
231	A convex windowless extrapolation chamber to measure surface dose rate from Ru/ Rh episcleral plaques. 2019 , 46, 2430-2443	4

230	Identification of canonical NFB (C-NFB) pathway in uveal melanoma and their relation with patient outcome. 2019 , 36, 271-290	5
229	Increased elasticity of melanoma cells after low-LET proton beam due to actin cytoskeleton rearrangements. 2019 , 9, 7008	5
228	Expression of immune checkpoint receptors Indoleamine 2,3-dioxygenase and T cell Ig and ITIM domain in metastatic versus nonmetastatic choroidal melanoma. 2019 , 8, 2784-2792	19
227	Regression rate of choroidal melanoma following iodine-125 brachytherapy is not associated with metastatic spread. 2019 , 29, 295-300	1
226	Cancer Staging. 2019 , 87-91	1
225	Clinical and histopathological features of choroidal melanoma-related enucleated eyes in a Spanish tertiary hospital. 2019 , 94, 225-231	
224	Clinical predictors of survival in metastatic uveal melanoma. 2019 , 63, 197-209	20
223	An improved treatment planning and quality assurance process for Collaborative Ocular Melanoma Study eye plaque brachytherapy. 2019 , 18, 658-667	3
222	Multi-Platform Omics Analysis for Identification of Molecular Characteristics and Therapeutic Targets of Uveal Melanoma. 2019 , 9, 19235	5
221	Cytokines concentrations in aqueous humor of eyes with uveal melanoma. 2019 , 98, e14030	9
220	Surface dose rate from a flat 106Ru/106Rh episcleral plaque measured with a planar windowless extrapolation chamber and un-laminated EBT3 film. 2019 , 121, 18-25	5
219	Uveal Melanoma in Ireland. 2019 , 5, 195-204	14
218	Novel Eye Plaque Designs for Brachytherapy of Iris and Ciliary Body Melanoma and the First Clinical Application. 2019 , 5, 220-227	3
217	Chromosome 3 is a valid marker for prognostic testing of biopsy material from uveal melanoma later treated by brachytherapy. 2019 , 24, 134-140	3
216	RELATIONSHIP OF CLINICAL FEATURES AND BASELINE TUMOR SIZE WITH GENE EXPRESSION PROFILE STATUS IN UVEAL MELANOMA: A Multi-institutional Study. 2019 , 39, 1154-1164	11
215	PHOTODYNAMIC THERAPY AS PRIMARY TREATMENT FOR SMALL CHOROIDDAL MELANOMA. 2019 , 39, 1319-1325	21
214	Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of 8.5 mm. 2020 , 104, 26-32	17
213	CORRELATION OF GENE EXPRESSION PROFILE STATUS AND AMERICAN JOINT COMMISSION ON CANCER STAGE IN UVEAL MELANOMA. 2020 , 40, 214-224	9

212	Quality of Life in Uveal Melanoma Patients in Ireland: A Single-Centre Survey. 2020 , 6, 99-106	3
211	Current Concepts in Ophthalmology. 2020 ,	
210	AAPM recommendations on medical physics practices for ocular plaque brachytherapy: Report of task group 221. 2020 , 47, e92-e124	15
209	Glaucoma After Iodine-125 Brachytherapy for Uveal Melanoma: Incidence and Risk Factors. 2020 , 29, 1-10	4
208	Ocular Tumors. 2020 , 968-998.e9	1
207	Intraocular Tumors. 2020 ,	
206	3D Wrap Ultra-Widefield Reconstruction in Stereotactic Radiosurgery for Choroidal Melanoma. 2020 , 6, 20-24	2
205	Quality of Life Concerns in Patients with Uveal Melanoma after Initial Diagnosis. 2020 , 6, 184-195	1
204	Molecular Insights and Emerging Strategies for Treatment of Metastatic Uveal Melanoma. 2020 , 12,	10
203	Prevention and treatment of the toxic tumour syndrome following primary proton beam therapy of choroidal melanomas. 2020 , 5, 22-28	
202	Uveal Melanoma-Derived Extracellular Vesicles Display Transforming Potential and Carry Protein Cargo Involved in Metastatic Niche Preparation. 2020 , 12,	8
201	Choroidal melanocytic tumors in dogs: A retrospective study. 2020 , 23, 987-993	3
200	Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan-Long-Term Overall Survival Negatively Correlates with Tumor Burden. 2020 , 2020, 5672048	2
199	Quantifying Subclinical and Longitudinal Microvascular Changes Following Episcleral Plaque Brachytherapy Using Spectral Domain-Optical Coherence Tomography Angiography. 2020 , 4, 499-508	7
198	Personalized treatment planning in eye brachytherapy for ocular melanoma: Dosimetric analysis on ophthalmic structure at risk. 2020 , 76, 285-293	4
197	Evaluation of Racial, Ethnic, and Socioeconomic Associations With Treatment and Survival in Uveal Melanoma, 2004-2014. 2020 , 138, 876-884	11
196	Brachytherapy in Belgium in 2018. A national survey of the brachytherapy study group of the Belgian Society for Radiotherapy and Oncology (BeSTRO). 2020 , 150, 245-252	0
195	Forty-year prognosis after plaque brachytherapy of uveal melanoma. 2020 , 10, 11297	16

194	Gene Expression Profiling in Uveal Melanoma: Five-Year Prospective Outcomes and Meta-Analysis. 2020 , 6, 360-367	13
193	Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma. 2020 , 15, 183	6
192	MORTALITY OF PATIENTS WITH UVEAL MELANOMA DETECTED BY DIABETIC RETINOPATHY SCREENING. 2020 , 40, 2198-2206	3
191	Intratumoral Heterogeneity in Uveal Melanoma. 2021 , 7, 17-25	
190	Evolution of Care of Orbital Tumors with Radiation Therapy. 2020 , 81, 480-496	1
189	Eye plaque brachytherapy versus enucleation for ocular melanoma: an analysis from the National Cancer Database. 2020 , 12, 303-310	5
188	Gamma knife radiosurgery for uveal melanomas and metastases: a systematic review and meta-analysis. 2020 , 21, 1526-1536	6
187	The Economic Value of MR-Imaging for Uveal Melanoma. 2020 , 14, 1135-1143	3
186	Molecular Genetics of Intraocular Tumors. 2020 , 35, 174-181	
185	Response Evaluation of Choroidal Melanoma After Brachytherapy Using Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI): Preliminary Findings. 2020 , 10, 825	3
184	Epidemiological Study of Uveal Melanoma from US Surveillance, Epidemiology, and End Results Program (2010-2015). 2020 , 2020, 3614039	14
183	Comparison of Iodide-125 and Ruthenium-106 Brachytherapy in the Treatment of Choroidal Melanomas. 2020 , 14, 339-346	6
182	Prophylactic Intravitreal Bevacizumab After Plaque Radiotherapy for Uveal Melanoma: Analysis of Visual Acuity, Tumor Response, and Radiation Complications in 1131 Eyes Based on Patient Age. 2020 , 9, 29-38	5
181	Blue-Light Fundus Autofluorescence Imaging following Ruthenium-106 Brachytherapy for Choroidal Melanoma. 2020 , 243, 303-315	1
180	Impact of uveal melanoma thickness on post-plaque radiotherapy outcomes in the prophylactic anti-vascular endothelial growth factor era in 1131 patients. 2020 , 48, 610-623	1
179	Uveal melanoma. 2020 , 6, 24	143
178	YAP Activity is Not Associated with Survival of Uveal Melanoma Patients and Cell Lines. 2020 , 10, 6209	8
177	Treatment of radiation maculopathy and radiation-induced macular edema: A systematic review. 2021 , 66, 441-460	5

176	The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019). 2021 , 27, 28-33	13
175	Five-Year Follow-up of Microincisional Vitrectomy Surgery, Endolaser Tumor Ablation, and Gene-Expression Profiling in Small Uveal Melanoma. 2021 , 5, 298-303	1
174	PET/CT and PET/MR in Melanoma and Sarcoma. 2021 ,	
173	Hypofractionated stereotactic photon radiotherapy of choroidal melanoma: 20-year experience. 2021 , 60, 207-214	1
172	A 45-year experience of uveal melanoma in Taiwan: Verification of American Joint Committee on Cancer staging system and prognostic factors. 2021 , 120, 1361-1368	1
171	Good long-term visual outcomes of parapapillary choroidal melanoma patients treated with proton therapy: a comparative study. 2021 , 41, 441-452	1
170	Patients presenting with metastases: stage IV uveal melanoma, an international study. 2021 ,	11
169	Brachytherapy for Posterior Uveal Melanomas. 2021 , 1-25	
168	Radiation Therapy in Ocular Melanoma. 2021 , 103-114	
167	Intra-operative ocular ultrasonography of iodine-125 brachytherapy plaques in patients with uveal melanoma. 2021 , 13, 126-134	2
166	Enucleation for Uveal Melanoma. 2021 , 1-11	
165	Estimating Cured Fractions of Uveal Melanoma. 2021 , 139, 174-181	10
164	Current molecular and clinical insights into uveal melanoma (Review). 2021 , 58,	25
163	In-vivo imaging for assessing tumor growth in mouse models of ocular melanoma. 2021 , 204, 108431	0
162	Automatic optimization of treatment dosimetry to improve visual outcomes in episcleral plaque brachytherapy. 2021 , 20, 433-445	
161	Autophagy-Related Long Non-coding RNA Signature as Indicators for the Prognosis of Uveal Melanoma. 2021 , 12, 625583	6
160	Update of the CLRP eye plaque brachytherapy database for photon-emitting sources. 2021 , 48, 3373-3283	1
159	Small High-Risk Uveal Melanomas Have a Lower Mortality Rate. 2021 , 13,	1

158	MR Imaging Pathologic Correlation of Uveal Melanomas Undergoing Secondary Enucleation after Proton Beam Radiotherapy. 2021 , 11, 4310	1
157	Uveal Melanoma.	1
156	Recent advancements in the management of retinoblastoma and uveal melanoma. 2021 , 10, 51	1
155	Hypoxia-dependent drivers of melanoma progression. 2021 , 40, 159	11
154	Uveal melanoma: Long-term survival. 2021 , 16, e0250939	3
153	Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging-Part II: treatment indications and complications. 2021 , 12, 67	4
152	Comprehensive assessment of the effect of eye plaque tilt on tumor dosimetry. 2021 , 20, 1289-1295	1
151	Metastatic Risk Factors Associated with Class 1A Uveal Melanoma Patients. 2021 , 13,	0
150	Staged Eye-Plaque Brachytherapy: A Novel Approach for Large Uveal Melanoma. 2021 , 6, 100712	1
149	Uveal Melanoma - Standardised Procedure in Diagnosis, Therapy and Surveillance. 2021 , 238, 761-772	
148	Proteomics of Primary Uveal Melanoma: Insights into Metastasis and Protein Biomarkers. 2021 , 13,	2
147	Long-term outcomes after enucleation or plaque brachytherapy of choroidal melanomas touching the optic disc. 2021 , 20, 1245-1256	3
146	Nation-Wide Trends in Incidence-Based Mortality of Patients with Ocular Melanoma in USA: 2000 to 2018. 2021 , 14, 4171-4176	1
145	Localized Choroidal Melanoma Managed by Pars Plana Endoresection, Endodiathermy, and Endolaser. 2021 , 13, e18077	
144	The Trends of Uveal Melanoma Research in the Past Two Decades and Future Perspectives. 2021 , 1-10	
143	Radioactive Iodine-125 in Tumor Therapy: Advances and Future Directions. 2021 , 11, 717180	2
142	Paired comparisons of mutational profiles before and after brachytherapy in asian uveal melanoma patients. 2021 , 11, 18594	0
141	Post-Brachytherapy Pigment Dispersion in Uveal Melanoma.. 2021 , 7, 396-400	

140	New Therapeutic Perspectives in the Treatment of Uveal Melanoma: A Systematic Review. 2021 , 9,	6
139	Melanoma. 2022 , 83-96	
138	Choroidal Melanoma with Ultrasound-Guided Episcleral Brachytherapy: Long-Term Results and Risk of Metastasis. 2021 , 7, 280-286	
137	Intraocular Tumours. 2021 , 125-179	
136	Intraocular and Orbital Cancers. 2021 ,	
135	Uveal Melanoma: A Review of Prognostic Factors for Metastases. 2021 , 9, 1-6	1
134	Eye: Choroidal melanoma, retinoblastoma, ocular adnexal lymphoma and eyelid cancers. 726-744	4
133	Malignant Melanoma of the Uvea. 2010 , 547-559	10
132	Recent Developments in Ocular Oncology. 2020 , 275-293	2
131	Uveal Malignant Melanoma: Management Options for Brachytherapy. 2014 , 173-188	2
130	Uveal Melanoma. 2010 , 1400-1421	2
129	A reappraisal of the significance of largest basal diameter of posterior uveal melanoma.	2
128	Clinical outcomes and secondary glaucoma after gamma-knife radiosurgery and Ruthenium-106 brachytherapy for uveal melanoma: a single institution experience. 2021 , 31, 38-48	2
127	Irreversible electroporation of human primary uveal melanoma in enucleated eyes. 2013 , 8, e71789	5
126	[Prognostic factors for uveal melanoma]. 2015 , 131, 90-95	5
125	[Size-based classification of choroidal melanoma and its role in treatment decision-making]. 2016 , 132, 4-7	2
124	Follow the nevus: the cost-utility of monitoring for growth of choroidal nevi. 2019 , 12, 1456-1464	1
123	Expression of EZH2 in uveal melanomas patients and associations with prognosis. 2017 , 8, 76423-76431	9

122	Sigma-1 and Sigma-2 receptor ligands induce apoptosis and autophagy but have opposite effect on cell proliferation in uveal melanoma. 2017 , 8, 91099-91111	10
121	Immunotherapy for Uveal Melanoma - Current Knowledge and Perspectives. 2020 , 27, 1350-1366	6
120	Visual Acuity, Contrast Sensitivity and Color Vision Three Years After Iodine-125 Brachytherapy for Choroidal and Ciliary Body Melanoma. 2015 , 9, 131-5	3
119	Genetics of Ocular Melanoma: Insights into Genetics, Inheritance and Testing. 2020 , 22,	9
118	Episcleral plaque brachytherapy using ¹²⁵ Ir seeds on the treatment of intraocular tumors: a single-institution experience in India. 2012 , 60, 289-95	3
117	Is Collaborative Ocular Melanoma Study (COMS) still relevant?. 2018 , 66, 1385-1387	7
116	Outcome Analysis of Visual Acuity and Side Effect after Ruthenium-106 Plaque Brachytherapy for Medium-sized Choroidal Melanoma. 2018 , 25, 103-107	7
115	Ocular melanoma. 2010 , 134, 1778-84	40
114	Silicone Oil and Iodine-125 Brachytherapy for Uveal Melanoma in High-Risk Patients. 2019 , 11, e5270	0
113	Uveal melanoma diagnosis and current treatment options (Review). 2021 , 22, 1428	2
112	Melanoma. 2008 , 1229-1252	
111	Eye, Orbit, and Adnexal Structures. 2008 , 1137-1175	
110	Brachytherapy for Posterior Uveal Malignant Melanoma. 2008 , 4899-4909	
109	Enucleation, Evisceration, and Exenteration. 2008 , 3519-3528	0
108	Malignant Melanoma of the Uvea. 2010 , 611-622	
107	Treatment of choroidal melanoma. 2010 , 389-395	
106	Vasculogenic mimicry. 2010 , 383-388	
105	Malignant and Benign Diseases of the Eye and Orbit. 2010 , 75-94	1

- 104 Surgical Resection of Metastatic Choroidal Melanoma in the Rib and Bronchus-A case report. **2010**, 43, 117-119
- 103 Unilateral temporal haemianopia in a patient with non-small cell lung cancer: intraocular metastasis despite chemotherapy. **2011**, 2011,
- 102 Brachytherapy. **2012**, 259-286
- 101 Collaborative Ocular Melanoma Study (COMS). **2013**, 21-24
- 100 Uveal Melanoma: Brachytherapy. **2013**, 381-385
- 99 Intraocular Tumours. **2014**, 119-175
- 98 Uveal Melanoma. **2014**, 165-169
- 97 Uveal Malignant Melanoma: The Collaborative Ocular Melanoma Study. **2014**, 229-238
- 96 Eye, Orbit, and Adnexal Structures. **2014**, 1002-1036.e6
- 95 Uveal Melanoma Mortality. **2014**, 263-273
- 94 Surgical management of radiation-related complications. **2014**, 232-239
- 93 Brachytherapy for uveal melanoma. **2014**, 134-146
- 92 Ocular Brachytherapy. **2016**, 63-69
- 91 Prognostic factors of choroidal melanoma in Slovenia, 1986-2008. **2016**, 50, 104-12 2
- 90 Atypical Presentation of Uveal and Conjunctival Melanoma in the Anterior Segment. 041-043
- 89 Ocular Melanoma. **2017**, 850-853
- 88 Eye Plaque Brachytherapy. **2017**, 197-217
- 87 Eye. 726-744

- 86 Uveal Melanoma. **2018**, 243-258
- 85 Ocular Melanoma. **2018**, 1-16
- 84 Ocular Plaque Brachytherapy for Uveal Melanoma and Retinoblastoma. **2019**, 261-270
- 83 Retrospective Review Of Uveal Melanoma Patients Treated With Fractionated Stereotactic Radiotherapy. **2019**, 1
- 82 Genetic Implications of Ocular Melanoma. **2019**, 37-46
- 81 Diagnosis and Management of Small Choroidal Melanoma. **2019**, 23-36
- 80 Clinical and histopathological features of choroidal melanoma-related enucleated eyes in a Spanish tertiary hospital. **2019**, 94, 225-231 2
- 79 Choroidal Melanoma: Clinical Trials and What Have We Learned from Them. **2020**, 93-102
- 78 Uveal Melanoma: Diagnosis, Classification and Management. **2020**, 71-80
- 77 Counseling for Patients with Choroidal Melanoma. **2020**, 299-308
- 76 Quantifying subclinical and longitudinal microvascular changes following episcleral plaque brachytherapy (EPB) using spectral-domain OCT angiography.
- 75 American brachytherapy society radiation oncology alternative payment model task force: Quality measures and metrics for brachytherapy. **2021**, 0
- 74 Metastatic disease of melanoma malignum choroid. **2020**, 25, 55-63
- 73 Future Directions of PET and Molecular Imaging and Therapy with an Emphasis on Melanoma and Sarcoma. **2021**, 233-246
- 72 Enucleation, Evisceration, and Exenteration. **2020**, 1-19
- 71 Comparison of iodine-125 plaque brachytherapy and gamma knife stereotactic radiosurgery treatment outcomes for uveal melanoma patients. **2021**, 1 1
- 70 Photodynamische Therapie bei Aderhautmelanom. **2008**, 51-55
- 69 Interdisciplinary Surveillance of Ocular Melanomas: Experiences in a German Tertiary Centre. **2021**, 238, 85-91

68	Changes in meibum composition following plaque brachytherapy for choroidal melanoma. 2020 , 5, e000614	
67	Long-term visual acuity results of treated and untreated radiation retinopathy (an AOS thesis). 2008 , 106, 325-35	24
66	Ocular melanoma: an overview of the current status. 2013 , 6, 1230-44	112
65	Brachytherapy of Uveal Melanomas with Ruthenium-106 Plaques. 2016 , 17, 5281-5285	2
64	Local tumor control and treatment related toxicity after plaque brachytherapy for uveal melanoma: A systematic review and a data pooled analysis. 2021 , 166, 15-25	0
63	Vasculogenic mimicry correlates to presenting symptoms and mortality in uveal melanoma. 2021 , 1	2
62	Uveal Melanoma: A Review of the Literature and Personal Experiences. 2021 , 6, 65-74	
61	Histopathologic and MR Imaging Appearance of Spontaneous and Radiation-Induced Necrosis in Uveal Melanomas: Initial Results.. 2022 , 14,	0
60	Clinical Outcomes after International Referral of Uveal Melanoma Patients for Proton Therapy.. 2021 , 13,	0
59	Intravitreal aflibercept combined with transpupillary thermotherapy in the treatment of refractory macular edema due to primary uveal melanoma. 2022 ,	
58	The unfolded protein response and the biology of uveal melanoma.. 2022 ,	
57	Preliminary Results of Uveal Melanoma Treated With Iodine-125 Plaques: Analysis of Disease Control and Visual Outcomes With 63 Gy to the Target Volume.. 2022 , 7, 100869	0
56	Radiological and clinical findings in uveal melanoma treated by plaque interventional radiotherapy (brachytherapy): Visual atlas and literature review on response assessment.. 2022 , 14, 96-106	0
55	Contemporary trends in management of uveal melanoma.. 2022 , 14, 123-129	
54	Surgical Resection of Intraocular Tumors (Partial Transscleral Sclerouvectomy Combined With Microinvasive Vitrectomy and Reconstruction of the Eyeball) in Asian Patients: Twenty-Five Years Results.. 2022 , 12, 768635	0
53	Long-term relative survival in uveal melanoma: a systematic review and meta-analysis. 2022 , 2,	1
52	Long Term Outcome Of Adjuvant Photodynamic Therapy after CyberKnife Radiotherapy For Choroidal Melanoma.. 2022 , 102840	1
51	Retrospective analysis of secondary enucleation for uveal melanoma after plaque radiotherapy.. 2022 , 22, 163	0

- 50 The long-term prognosis of patients with untreated primary uveal melanoma: A systematic review and meta-analysis.. **2022**, 172, 103652 ○
- 49 Tebentafusp for the treatment of metastatic uveal melanoma.. **2022**, ○
- 48 New Perspectives for Eye-Sparing Treatment Strategies in Primary Uveal Melanoma.. **2021**, 14, ○
- 47 Efficacy and Safety of Immune Checkpoint Blockades in the Treatment of Ocular Melanoma: A Systematic Review and Meta-Analysis.. **2021**, 11, 781162 ○
- 46 Three-year outcomes of uveal melanoma treated with intra-operative ultrasound-guided iodine-125 brachytherapy using custom-built eye plaques.. **2022**, 14, 130-139 ○
- 45 The rationale for treating uveal melanoma with adjuvant melatonin: a review of the literature.. **2022**, 22, 398 1
- 44 Association between Subjective and Objective Assessment of Enucleation Outcome Depending on the Presence of an Orbital Implant in Patients with Uveal Melanoma.. **2022**, 11, ○
- 43 Enucleation for Uveal Melanoma. **2022**, 7717-7727 ○
- 42 Brachytherapy for Posterior Uveal Melanomas. **2022**, 7691-7715 ○
- 41 Enucleation, Evisceration, and Exenteration. **2022**, 5419-5437 ○
- 40 A Retrospective Analysis of 10 Years of Liver Surveillance Undertaken in Uveal Melanoma Patients Treated at the Supraregional "Liverpool Ocular Oncology Centre", UK.. **2022**, 14, ○
- 39 Oncology. **2012**, 594-634 ○
- 38 Ocular malignancies treated with iodine-125 low dose rate (LDR) brachytherapy at a single high-volume institution: A retrospective review. **2022**, ○
- 37 Ocular Malignancies. **2022**, 201-224 ○
- 36 Laser Treatment for Choroidal Melanoma: Current Concepts. **2022**, ○
- 35 Local recurrence of uveal melanoma and concomitant brain metastases associated with an activating telomerase promoter mutation seven years after secondary enucleation. **2022**, 101607 ○
- 34 Amelanotic Uveal Melanomas Evaluated by Indirect Ophthalmoscopy Reveal Better Long-Term Prognosis Than Pigmented Primary Tumours: A Single Centre Experience. **2022**, 14, 2753 ○
- 33 The Adrenergic Receptor Antagonist Carvedilol Elicits Anti-Tumor Responses in Uveal Melanoma 3D Tumor Spheroids and May Serve as Co-Adjuvant Therapy with Radiation. **2022**, 14, 3097 1

- 32 Treatment of uncontrolled intraocular pressure secondary to uveal melanoma status post plaque radiotherapy with ab interno XEN gel stent implantation. **2022**, 27, 101610 ○
- 31 Ruthenium-106 plaque radiotherapy for uveal melanoma: analysis of tumor dimension and location on anatomical and functional results. **2022**, 22, ○
- 30 Long-term survival of uveal melanoma patients with respect to clinical, hemodynamic and morphological characteristics of the tumor. **2022**, 15, 85-91
- 29 Retinoblastoma and uveal melanoma in Jordan: incidence, demographics, and survival (2011-2020). 1-8 ○
- 28 Importance of Optical Coherence Tomography and Optical Coherence Tomography Angiography in the Imaging and Differentiation of Choroidal Melanoma: A Review. **2022**, 14, 3354 1
- 27 30 years of ocular proton therapy, the Nice view. **2022**, ○
- 26 Uveal Melanoma.
- 25 A systematic comparison of dose distributions delivered in iodine-125 plaque brachytherapy and proton radiation therapy for ocular melanoma. **2022**, ○
- 24 Characteristics, Treatments, and Survival of Uveal Melanoma: A Comparison between Chinese and American Cohorts. **2022**, 14, 3960
- 23 Chemosaturation of the Liver: An Update.
- 22 Consensus statement for metastatic surveillance of uveal melanoma in Scotland. ○
- 21 Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases. 12, ○
- 20 Every other day stereotactic radiation therapy for the treatment of uveal melanoma decreases toxicity. **2022**, 176, 39-45 ○
- 19 Outcomes of fractionated CyberKnife radiosurgery in patients with choroidal malignant melanoma. 1-5 ○
- 18 Adjuvant Melatonin for Uveal Melanoma (AMUM): Protocol for a Randomized Open-label Phase III Study. ○
- 17 Post-enucleation outcomes of patients with uveal melanoma in Scotland. ○
- 16 Sex-based differences in early and late uveal melanoma-related mortality. 1
- 15 The prognostic implication of visual acuity at the time of uveal melanoma diagnosis. ○

- 14 Robotic CyberKnife Radiosurgery for the Treatment of Choroidal and Ciliary Body Melanoma. **2023**, ○
- 13 Ocular Complications of Radiotherapy in Uveal Melanoma. **2023**, 15, 333 ○
- 12 Advances in the clinical management of uveal melanoma. 1
- 11 Prognostic Value of BAP1 and Preferentially Expressed Antigen in Melanoma (PRAME) Immunohistochemistry in Uveal Melanomas. **2023**, 100081 ○
- 10 Choroidal melanoma tumor profile and treatment pattern for newly diagnosed patients at a reference public hospital in Sao Paulo, Brazil. **2022**, 22, ○
- 9 Ocular Brachytherapy (Interventional Radiotherapy): Preserving the Vision. **2023**, ○
- 8 Postoperative Echography for Optimization of Radiation Dosimetry in Patients with Uveal Melanoma Treated with Plaque Brachytherapy. **2023**, ○
- 7 Basis, Diagnosis, and Treatment of Uveal Melanoma. ○
- 6 Impact of tumour volume and treatment delay on the outcome after linear accelerator-based fractionated stereotactic radiosurgery of uveal melanoma. bjo-2022-322750 ○
- 5 The future of clinical trials of myopia control. **2023**, 43, 525-533 ○
- 4 Genetic status affects disease-specific mortality but not the incidence of local recurrence in patients with uveal melanoma. **2023**, ○
- 3 Adjuvant melatonin for uveal melanoma (AMUM): protocol for a randomized open-label phase III study. **2023**, 24, ○
- 2 Anatomical and Functional Outcomes after Endoresection and Adjuvant Ruthenium Brachytherapy for Uveal Melanoma: A Single-Center Experience. **2023**, 13, 902 ○
- 1 Current management of uveal melanoma: A review. ○